Dublin, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics - A Global Market Overview" report has been ...
Trace Neuroscience Launches with $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases, ...
Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in ...
Hosted on MSN1d
Ozempic and Viagra, among the more than 80 drugs expected to work against Alzheimer's in the coming yearsIn phase II and phase III, there are several compounds targeting tau, especially monoclonal antibodies (such as E2814, ...
Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.
Injecting IgG into young mice induced aging in multiple tissues and organs, while reducing IgG using antisense ...
In a study led by researchers at the NUS Yong Loo Lin School of Medicine, extracellular vesicles loaded with customizable ...
The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September, and according to ...
Ionis Pharmaceuticals posted better-than-expected revenue in the third quarter, but faced challenges as it prepares to bring ...
Begin your TipRanks Premium journey today. Percheron Therapeutics (PERCF) Company Description: Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals.
Researchers have used microcellular "drones" to deliver antisense oligonucleotide therapeutics to lung cancer cells.
Ultragenyx Pharmaceutical Inc. (RARE) announced Phase 1/2 data in support of the Phase 3 Aspire study for GTX-102, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback